Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Operating Margin (2021 - 2024)

Goldenwell Biotech's Operating Margin history spans 4 years, with the latest figure at 45674.05% for Q4 2024.

  • For Q4 2024, Operating Margin fell 3767444.0% year-over-year to 45674.05%; the TTM value through Sep 2025 reached 35406.33%, down 1131961.0%, while the annual FY2024 figure was 19853.96%, 1851158.0% down from the prior year.
  • Operating Margin reached 45674.05% in Q4 2024 per GWLL's latest filing, down from 34402.88% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 2261.3% in Q2 2021 to a low of 45674.05% in Q4 2024.
  • Average Operating Margin over 4 years is 9772.08%, with a median of 5181.45% recorded in 2023.
  • Peak YoY movement for Operating Margin: skyrocketed 604653bps in 2023, then tumbled -3767444bps in 2024.
  • A 4-year view of Operating Margin shows it stood at 133.52% in 2021, then soared by 92bps to 10.49% in 2022, then tumbled by -76144bps to 7999.62% in 2023, then crashed by -471bps to 45674.05% in 2024.
  • Per Business Quant, the three most recent readings for GWLL's Operating Margin are 45674.05% (Q4 2024), 34402.88% (Q2 2024), and 7999.62% (Q4 2023).